**Psoriasis is associated with elevated gut IL-1α and intestinal microbiome alterations in a Central Asian population**

# Sergey Yegorov1,2\*, Dmitriy Babenko3, Samat Kozhakhmetov 4, Lyudmila Akhmaltdinova3, Irina Kadyrova3, Ayaulym Nurgozhina4, Madiyar Nurgaziyev4, Sara V. Good5, Gonzalo H. Hortelano,1 Bakytgul Yermekbayeva6, Almagul Kushugulova4

1School of Science and Humanities, Nazarbayev University, Astana, Kazakhstan

2 Faculty of Education and Humanities, Suleyman Demirel University, Almaty, Kazakhstan

3 Karaganda Medical University Research Centre, Karaganda, Kazakhstan

4Laboratory of Human Microbiome and Longevity, National Laboratory Astana, Nazarbayev University, Nur-Sultan, Kazakhstan

5 Department of Biology, University of Winnipeg, Winnipeg, Canada

6 University Medical Center Corporate Fund, Nur-Sultan, Kazakhstan

**Supplementary Table 1.** Description of the analytes assessed by multiplex ELISA in the stool supernatants of psoriasis patients and controls

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **#** | **Cytokine** | **Category** | **Full name**  | **Alternative name** | **Lowest level of detection** |
| **1** | IL-1RA | Receptor antagonist | Interleukin-1 receptor antagonist | DIRA; IRAP; IL1F3; IL1RA; MVCD4; | 8.3 pg/mL |
| **2** | IL-1 alpha | Proinflammatory cytokine | Interleukin-1 alpha | IL1 | 9.4 pg/mL |
| **3** | IL-1beta | Proinflammatory cytokine | Interleukin 1 beta | IL-1 | 0.8 pg/mL |
| **4** | IL-2 | Lymphocyte growth factors | Interleukin 2 | TCGF; lymphokine | 1.0 pg/mL |
| **5** | IL-3 | Colony-stimulating factors | Interleukin 3 | MCGF; MULTI-CSF | 0.7 pg/mL |
| **6** | IL-4 | Th2-–interleukin | Interleukin 4 | BSF1 | 4.5 pg/mL |
| **7** | IL-5 | Th2-–interleukin | Interleukin 5 | EDF; TRF | 0.5 pg/mL |
| **8** | IL-6 | Proinflammatory cytokine | Interleukin 6 | - | 0.9 pg/mL |
| **9** | IL-7 | Hematopoietic growth factor | Interleukin 7 | - | 1.4 pg/mL |
| **10** | IL-8 | Chemokine | Interleukin 8 | CXCL8 | 0.4 pg/mL |
| **11** | IL-9 | Th9-–interleukin | Interleukin 9 | P40; HP40 | 1.2 pg/mL  |
| **12** | IL-10 | Anti-inflammatory cytokines | Interleukin 10 | CSIF; TGIF; GVHDS | 1.1 pg/mL |
| **13** | IL-12p40 | Proinflammatory cytokineCytokine for th17 | Interleukin-12 p40 | Interleukin-23 | 7.4 pg/mL |
| **14** | IL-12P70 | Th1 –interleukin  | Interleukin 12B p70 | CLMF; NKSF; CLMF2; IMD28; IMD29; NKSF2; | 0.6 pg/mL |
| **15** | IL-13  | Th2-–interleukin | Interleukin 13 | P600 | 1.3 pg/mL |
| **16** | IL-15 | Lymphocyte growth factors | Interleukin 15 |  - | 1.2 pg/mL |
| **17** | IL-17A | Proinflammatory cytokine | Interleukin 17a | CTLA8 | 0.7 pg/mL |
| **18** | IFN alpha2 | Type I IFN | Interferon alpha 2 | IFNα2, IFNA2B | 2,9 pg/mL |
| **19** | IFN gamma | Type II IFN | Interferon gamma | IFG; IFI | 0.8 pg/mL |
| **20** | TNF alpha | Proinflammatory cytokine | Tumor necrosis factor alpha | DIF | 0.7 pg/mL |
| **21** | TNF beta | Proinflammatory cytokine | Tumor necrosis factor-beta | Lymphotoxin-alpha (LT-α) | 1.5 pg/mL |
| **22** | TGF-alpha | Growth factor | Transforming growth factor alpha | - | 0.8 pg/mL |
| **23** | EGF | Growth factor | Epidermal growth factor | URG; HOMG4 | 2,8 pg/mL |
| **24** | FGF-2 | Growth factor | Fibroblast growth factor 2 | BFGF; FGFB; HBGF-2 | 7,6 pg/mL |
| **25** | PDGF AA | Growth factors | Platelet-derived growth factor AA | PDGF1 | 0.4 pg/mL |
| **26** | PDGF AB/BB | Growth factors | Platelet-derived growth factor AB/BB | PDGF2 | 2.2 pg/mL |
| **27** | VEGF A | Growth factors | Vascular endothelial growth factor A | VPF; MVCD1 | 26.3 pg/mL |
| **28** | G-CSF | Colony-stimulating factors | Granulocyte-colony stimulating factor | Colony-stimulating factor 3 | 1.8 pg/mL |
| **29** | GM-CSF | Colony-stimulating factors | Granulocyte-macrophage colony-stimulating factor | Colony-stimulating factor 2 | 7.5 pg/mL |
| **30** | Fit-3L | Growth factors | Fms-related tyrosine kinase 3 ligand | CD135 | 5.4 pg/mL |
| **31** | Eotaxin | Chemokine | Eosinophil chemotactic protein | CCL11 | 4,0 pg/mL |
| **32** | Fractalkine  | Chemokine | Fractalkine | CX3CL1, neurotactin | 22.7 pg/mL |
| **33** | Gro | Chemokine | human growth-regulated oncogene | CXCL1;  | 9.9 pg/mL |
| **34** | IP-10 | Chemokine | Interferon gamma-induced protein 10 | CXCL10 | 8.6 pg/mL |
| **35** | MCP-3 | Chemokine | Monocyte-chemotactic protein 3 | CCL7 | 3.8 pg/mL |
| **36** | MCP-1 | Chemokine | Monocyte-chemotactic protein 1 | CCL2 | 1.9 pg/mL |
| **37** | MDC | Chemokine | Macrophage-derived chemokine | CCL22 | 3.6 pg/mL |
| **38** | MIP-1 alpha | Chemokine | Macrophage inflammatory protein 1-alpha | CCL3 | 2.9 pg/mL |
| **39** | MIP-1 beta | Chemokine | Macrophage inflammatory protein 1- beta | CCL4 | 3.0 pg/mL |
| **40** | RANTES | Chemokine | Regulated on activation, normal t cell expressed and secreted | CCL5 | 1.2 pg/mL |
| **41** | sCD40L | Costimulatory protein | CD40 ligand | IGM; IMD3; TRAP; gp39; CD154;  | 5.1 pg/mL |
| **42** | IgA  | Immunoglobulin | Immunoglobulin A | - | 0.40 ng/mL |
| **43** | IgG1  | Immunoglobulin | Immunoglobulin G1 | - | 13.0 ng/mL |
| **44** | IgG2  | Immunoglobulin | Immunoglobulin G2 | - | 33.0 ng/mL |
| **45** | IgG3  | Immunoglobulin | Immunoglobulin G3 | - | 0.08 ng/mL |
| **46** | IgG4  | Immunoglobulin | Immunoglobulin G4 | - | 0.13 ng/mL |
| **47** | IgM  | Immunoglobulin | Immunoglobulin M | - | 1.0 ng/mL |

**Supplementary Table 2. Cytokine and immunoglobulin concentrations measured in stool supernatants of the psoriasis+ participants and controls.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Cytokine/Ig** | **Median concentration (IQR), pg/ml** | **Detectable in >50% of participants** | **P value\*** |
| **All participants**  | **Controls** | **PSRS+** |
| **Cytokines and chemokines** |
| EGF | 0 (0-22.77) | 0 (0-30.82) | 0 (0-23.29) | yes | 1 |
| Eotaxin | 2.92 (2.84-3.18) | 2.89 (2.82-3.22) | 2.96 (2.85-3.23) | yes | 0.821 |
| FGF-2 | 3.28 (0.99-6.97) | 2.49 (0.89-28.71) | 3.43 (1.08-5.76) | yes | 0.974 |
| G-CSF | 0.92 (0.56-3.22) | 0.74 (0.44-8.79) | 1.54 (0.68-4.92) | yes | 0.456 |
| GM-CSF | 4.55 (1.21-12.04) | 3.73 (1.78-10.47) | 4.55 (1.18-15.85) | yes | 0.923 |
| IL-1 alpha | 532.72 (210.66-1058.24) | 215.34 (138.05-313.8) | 901.82 (559.51-1245.37) | yes | 0.007 |
| IL-12p70 | 1.61 (0.54-14.11) | 1.14 (0.07-3.81) | 2.53 (1-49.03) | yes | 0.08 |
| IL-13 | 2.49 (2.22-2.88) | 2.42 (2.16-3.27) | 2.57 (2.25-2.92) | yes | 0.722 |
| IL-17A | 1 (0-6.03) | 0.46 (0-2.92) | 1.33 (0-14.43) | yes | 0.418 |
| IL-1RA | 5.95 (1.19-99.02) | 2.26 (1.04-205.82) | 12.87 (1.29-76.62) | yes | 0.418 |
| IL-3 | 2.51 (1.65-6.03) | 2.74 (1.5-3.81) | 2.4 (1.79-12.71) | yes | 0.674 |
| IL-5 | 0.9 (0.79-2.14) | 0.92 (0.7-1.37) | 0.88 (0.8-8.6) | yes | 0.497 |
| IL-8 | 2.71 (2.65-2.93) | 2.69 (2.65-2.93) | 2.74 (2.65-3.02) | yes | 0.582 |
| IP-10 | 26.86 (18.63-36.3) | 26.86 (14.93-35.23) | 27.96 (21.41-37.74) | yes | 0.539 |
| MCP-1 | 2.87 (2.71-4.11) | 2.85 (2.7-3.21) | 3.03 (2.73-27.35) | yes | 0.381 |
| MDC | 1.5 (0-5.03) | 1.65 (0-6.09) | 0.83 (0-5.03) | yes | 0.821 |
| MIP-1 alpha | 3.1 (3.09-3.23) | 3.1 (3.08-3.16) | 3.13 (3.1-3.25) | yes | 0.203 |
| MIP-1 beta | 22.86 (10.53-36.76) | 22.86 (10.18-30.45) | 22.27 (10.05-68.49) | yes | 0.872 |
| PDGF AA | 1.91 (1.86-2.02) | 1.9 (1.85-2.09) | 1.93 (1.87-2.01) | yes | 0.821 |
| PDGF AB/BB | 0.11 (0.08-4.41) | 0.09 (0.08-0.23) | 0.16 (0.08-1584.97) | yes | 0.418 |
| RANTES | 0.16 (0.16-0.17) | 0.16 (0.16-0.18) | 0.16 (0.16-0.17) | yes | 0.582 |
| sCD40L | 2.44 (2.13-5.78) | 2.43 (2.25-4.52) | 2.58 (2.12-12.31) | yes | 0.674 |
| TGF-alpha | 2.78 (2.73-2.83) | 2.78 (2.74-2.87) | 2.77 (2.73-2.87) | yes | 0.582 |
| TNF alpha | 2.42 (2.32-3.3) | 2.35 (2.3-2.75) | 2.49 (2.37-4.68) | yes | 0.254 |
| TNF beta | 1.47 (1.43-1.58) | 1.45 (1.43-1.66) | 1.48 (1.42-1.65) | yes | 1 |
| VEGF A | 0.79 (0.39-2.83) | 0.72 (0.45-8.36) | 0.8 (0.38-3.99) | yes | 0.771 |
| FIt-3L | 0 (0-0) | 0 (0-1.51) | 0 (0-0) | <50 | 0.571 |
| Fractalkine | 0 (0-27.85) | 0 (0-51.38) | 0 (0-81.07) | <50 | 0.646 |
| GRO | 0 (0-0) | 0 (0-0) | 0 (0-0) | <50 | 1 |
| IFN-alpha2 | 0 (0-57.76) | 0 (0-72.62) | 0 (0-45.11) | <50 | 1 |
| IFN-gamma | 0 (0-1.33) | 0 (0-2.31) | 0.06 (0-1.64) | <50 | 0.415 |
| IL-1 beta | 0.86 (0-20.78) | 0.11 (0-25.88) | 5.67 (0-18.7) | <50 | 1 |
| IL-10 | 0 (0-1.34) | 0 (0-0.98) | 0.21 (0-2.62) | <50 | 0.231 |
| IL-12p40 | 0 (0-3.79) | 0 (0-3.79) | 0 (0-41.24) | <50 | 1 |
| IL-15 | 0 (0-36.44) | 0 (0-11.02) | 2.55 (0-165.69) | <50 | 0.231 |
| IL-2 | 0 (0-5.61) | 0 (0-1.25) | 0.12 (0-84.24) | <50 | 0.415 |
| IL-4 | 0 (0-30.69) | 0 (0-40.27) | 0 (0-39.07) | <50 | 1 |
| IL-6 | 0 (0-5.23) | 0 (0-0) | 0 (0-67.44) | <50 | 0.323 |
| IL-7 | 0 (0-10.14) | 0 (0-7.41) | 2.41 (0-11.78) | <50 | 0.204 |
| IL-9 | 0 (0-0) | 0 (0-0) | 0 (0-3.3) | <50 | 0.594 |
| MCP-3 | 0 (0-8.6) | 0 (0-0) | 0 (0-98.33) | <50 | 0.323 |
| **Immunoglobulins** |
| IgA  | 3.28 (0.7-25.49) | 2.13 (0.87-13.05) | 7.6 (0.55-58.26) | yes | 0.403 |
| Ig G1  | 4.1 (0-16.09) | 0 (0-14.95) | 4.53 (0-17.22) | yes | 0.308 |
| Ig M  | 0.66 (0.46-0.95) | 0.52 (0.45-0.7) | 0.78 (0.45-1.06) | yes | 0.211 |
| Ig G2  | 0 (0-0) | 0 (0-0) | 0 (0-0) | <50 | 1 |
| Ig G3  | 0 (0-0) | 0 (0-0) | 0 (0-0) | <50 | 1 |
| Ig G4  | 0 (0-0.06) | 0 (0-0.02) | 0.02 (0-0.11) | <50 | 0.433 |

**Sample sizes: all (N=22-29), controls (N=7-10), psoriasis+ (N=12=19). \*Independent-Samples Mann-Whitney U Test was used for analytes detectable in >50% of the participants, Chi-square tests were used for analytes detectable in <50% of the participants.**

**Supplementary Table 3. Socio-demographic and psoriasis-specific characteristics of participants with measurable IL-1a, N=19.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Participant characteristic** | **Psoriasis group (N=12)** | **Controls (N=7)** | **P value** |
| **Median age (IQR)** | 35.5 (31.3-37.8) | 32.0 (31.0-33.0) | 0.097 |
| **Men, n (%)** | 7 (58.3) | 4 (33.3) | 0.960 |
| **Mean body mass index (range)^** | 23.9 (18.6-29.0) | 23.2 (18.6-32.7) | 0.738 |
| **Married, n (%)** | 8 (66.7) | 7 (100) | 0.086 |
| **Psoriasis type** |  |  |  |
| Vulgaris | 9 (75.0) | **-** | **-** |
| Guttate | 2 (16.7) | **-** | **-** |
| Palmoplantar | 1 (8.3) | **-** | **-** |
| **Psoriasis present in a parent** | 5 (41.7) | **-** | **-** |
| **Time since psoriasis first noted** |  |  |  |
| <5 years | 2 (16.7) | **-** | **-** |
| 5-10 years | 2 (33.3) | **-** | **-** |
| >10 years | 6 (50.0) | **-** | **-** |
| **Head hair damage present** | 10 (83.3) | **-** | **-** |
| **Nail damage present** | 1 (8.3) | **-** | **-** |
| **Median PASI (IQR)** | 10.8 (6.5-18.9) | **-** | **-** |

BMI, body mass index; PASI, Psoriasis Area and Severity Index



**Supplementary Figure 1.** Microbial speciesβ-diversity measured in the gut of psoriasis+ individuals and controls